drugset / Trial / NCT00673426

Safety Evaluation of Use Sodic Enoxaparin

NCT00673426

Phase 3 Completed 60 enrolled Azidus Brasil
RandomizedParallel-groupDouble-blindPrevention

Summary

The purpose of this study was to evaluate safety, not inferiority clinical and pharmacodynamic profile of the drug Enoxaparin Sodium produced by laboratory Blausiegel when compared with Clexane product, produced by Laboratory Sanofi-Aventis in 60 patients with Chronic Renal Desease.

Timeline

Start
2008-01
Primary completion
2008-03
Completion
2008-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Enoxaparin sodium Other / unclassified 1 mg/kg

Indications